Brendan Sweeny, MD
Hospitalist · Greenwood, INNPI 1518287473
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $367 and has fallen 89.4% since, to $39 in 2024.
Across 45 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$129
- AbbVie$124
- Amgen$81
- GSK$64
- Boehringer Ingelheim$45
- Pfizer$42
- plus $246 from 10 others
What the payments were for
- Food & beverage$72299%
- Education$81%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $129 |
| AbbVie(2 entities) | 8 | $124 |
| Amgen | 5 | $81 |
| GSK | 5 | $64 |
| Boehringer Ingelheim | 3 | $45 |
| Pfizer | 3 | $42 |
| Medtronic | 1 | $39 |
| Lilly USA, LLC | 3 | $37 |
| Biocomposites Inc | 1 | $36 |
| Merck | 2 | $27 |
| Johnson & Johnson | 2 | $25 |
| Novo Nordisk | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $21 |
| Amarin Pharma, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$105
How this compares
$730 in reported general payments places this provider in the 85th percentile of 423 hospitalist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,121 | $316,326 |
| AvycazCeftazidime/Avibactam | 31 | $121,036 |
| Enbrel SureclickEtanercept | 13 | $104,401 |
| XifaxanRifaximin | 46 | $84,551 |
| TrulicityDulaglutide | 114 | $81,516 |
| JardianceEmpagliflozin | 254 | $75,225 |
| XareltoRivaroxaban | 169 | $47,787 |
| MounjaroTirzepatide | 54 | $47,637 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 138 | $43,746 |
| JanuviaSitagliptin Phosphate | 130 | $38,828 |
| MyrbetriqMirabegron | 157 | $36,744 |
| OzempicSemaglutide | 34 | $34,884 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $32,581 |
| AustedoDeutetrabenazine | 12 | $28,601 |
| LinzessLinaclotide | 50 | $28,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $42 | $329,1611,162 claims |
| AbbVieAvycaz, Linzess, Ubrelvy, Creon | $124 | $180,167124 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $37 | $129,153168 claims |
| GSKArexvy, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta | $64 | $95,277272 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $45 | $86,142273 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $12 | $84,55146 claims |
| Johnson & JohnsonXarelto | $25 | $47,787169 claims |
| MerckJanuvia | $27 | $38,828130 claims |
| Novo NordiskOzempic | $24 | $34,88434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 423 hospitalist providers in Indiana.
Other hospitalist in Greenwood
- Ashraf AbdelhafezGreenwood$1K
- Bisher ZuhdiGreenwood$915
- Ajay PonugotiGreenwood$812
- Joseph AbdayemTerre Haute$13K
- James KruegerEvansville$11K
- Yu LiuDecatur$6K
- Laarni MorenoElkhart$5K
- Harold RahmingDyer$5K
- Jai Kumar KhatriIndianapolis$4K
- Sanjay RaikarMichigan City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.